Elahere (Mirvetuximab Soravtansine)

 Elahere (mirvetuximab soravtansine-gynx) injection, a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate is used in the treatment of adult patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who are FRα positive and have been treated with platinum-based chemotherapy. It is given to patients who have already had one to three lines of therapy. This medicinal product works by binding to folate receptor alpha (FRα) on cancer cells and internalizing a microtubule inhibitor which retards their growth and metastasis. This allows patients with cancer who are refractory to platinum-based chemotherapy to enhance their outcomes.

Recommended Dosage: The recommended dosage of Elahere injection is 6 mg/kg adjusted ideal body weight (AIBW) administered once every 3 weeks (21-day cycle) as an intravenous (IV) infusion until there is evidence of disease progression or unacceptable toxicity. Dosing based on adjusted ideal body weight reduces exposure variability for patients who are either under or overweight. 

• Treatment with Elahere injection leads to problems such as seeing fuzzy images, having dry eyes, or looking at light. Follow-up appointments should be scheduled regularly. If your vision seems to worsen, it is best to consult with your physician. If eye discomfort occurs, contact your doctor to discuss management.
• Serious lung inflammation (pneumonitis) may occur, leading to cough, breathing issues, or chest discomfort. If symptoms appear, seek immediate medical help. Doctors may recommend dose adjustments or stopping treatment to prevent severe breathing problems that could become life-threatening if untreated.
• Some patients experience nerve damage while using Elahere 100 mg/20 mL, causing tingling, numbness, or weakness in the hands or feet. Report symptoms early to avoid permanent nerve damage. Doctors may lower the dose or stop treatment if symptoms become severe and affect daily activities.
• This therapeutic drug can harm an unborn baby if used during pregnancy. Women must use effective contraception while on treatment and for some time after the last dose. If pregnancy occurs, inform your doctor immediately to discuss risks and potential alternative treatments.
• This medication may pass into breast milk, posing risks to the baby. Avoid breastfeeding while on Elahere and for a specific period after treatment ends. Consult a doctor to understand the safest timeline for resuming breastfeeding after completing therapy.

What documents are required to import ELAHERE to India?

Indian Pharma Network can source ELAHERE (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Elahere®?

Mirvetuximab soravtansine-gynx is a Generic Name for the trade name drug Elahere®.

What is the Manufacturer’s Name of Elahere®?

Elahere® is manufactured by AbbVie Inc.

Is Elahere® approved by the FDA?

Yes, Elahere® is approved by the FDA. Date of first approval: November 14, 2022.

What is the dosage and form of Elahere® supplied?

Elahere is supplied in Injection: 100 mg/20 mL (20 mg/mL) in a single-dose vial for intravenous (IV) use.

What are the most common side effects of Elahere® 100 mg/20 mL injection? 

The most common side effects of Elahere® are fatigue, diarrhea, blurred vision, nausea, abdominal pain, dry eye, keratopathy, peripheral neuropathy, musculoskeletal pain, constipation, decreased appetite, and vomiting.

How much does Elahere® 100 mg/20 mL injection cost in India?

Prices of Elahere 100 mg/20 mL mg injections may fluctuate over time because of market dynamics and regulatory changes. To get the most accurate information on Elahere 100 mg/20 mL injections cost in India, please Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Elahere® 100 mg/20 mL injections be available in SAARC countries? 

Apart from Gulf countries, Elahere® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Elahere® injections in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Elahere® 100 mg/20 mL injections online in India?

Yes, one can buy Elahere 100 mg/20 mL online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Elahere® injections through legal channels. 

Do you ship Elahere (Mirvetuximab Soravtansine 100 mg/20 mL Injection) to my country?

Yes, we can ship Elahere to various countries worldwide. Send your inquiry to buy Elahere in Afghanistan, Antigua & Barbuda, Aruba, Albania, Algeria, Angola, American Samoa, Anguilla, Armenia, Bahamas, Belgium, Benin, Bangladesh, Barbados, Belarus, Belize, Bermuda, Bhutan, Bolivia, Bosnia & Herzegovina, Botswana, Bouvet Island, British Indian Ocean Territory, British Virgin Islands, Brunei, Burkina Faso, Burundi, Cameroon, Cape Verde, Cayman Islands, Central African Republic, Chad, China, Christmas Island, Cocos (Keeling) Islands, Comoros, Congo – Brazzaville, Congo – Kinshasa, Cook Islands, Cuba, Czechia, Côte d’Ivoire, Djibouti, Dominica, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Falkland Islands, Faroe Islands, Fiji, French Guiana, French Polynesia, French Southern Territories, Gabon, Gambia, Gibraltar, Greenland, Grenada, Guadeloupe, Guam, Guernsey, Guinea, Guinea-Bissau, Guyana, Haiti, Heard & McDonald Islands, Honduras, Hong Kong SAR China, Hungary, Iceland, Indonesia, Iran, Isle of Man, Jersey, Kazakhstan, Kiribati, Kyrgyzstan, Laos, Lesotho, Liberia, Liechtenstein, Luxembourg, Macao SAR China, Madagascar, Malaysia, Maldives, Mali, Malta, Marshall Islands, Martinique, Mauritania, Mauritius, Mayotte, Micronesia, Moldova, Monaco, Mongolia, Montserrat, Morocco, Mozambique, Myanmar (Burma), Namibia, Nauru, New Caledonia, Nicaragua, Niger, Niue, Norfolk Island, North Korea, North Macedonia, Northern Mariana Islands, Palau, Palestinian Territories, Panama, Papua New Guinea, Philippines, Pitcairn Islands, Portugal, Russia, Rwanda, Réunion, Saint Barthélemy, Samoa, San Marino, Senegal, Seychelles, Sierra Leone, Slovakia, Solomon Islands, Somalia, South Africa, South Georgia & South Sandwich Islands, South Korea, St. Helena, St. Kitts & Nevis, St. Lucia, St. Martin, St. Pierre & Miquelon, St. Vincent & Grenadines, Sudan, Suriname, Svalbard & Jan Mayen, Syria, São Tomé & Príncipe, Taiwan, Province of China, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tokelau, Tonga, Trinidad & Tobago, Tunisia, Turkey, Turkmenistan, Turks & Caicos Islands, Tuvalu, U.S. Outlying Islands, U.S. Virgin Islands, Uganda, Ukraine, Uruguay, Uzbekistan, Vanuatu, Vatican City, Vietnam, Wallis & Futuna, Western Sahara, Yemen, Zambia, Åland Islands.

What are the storage conditions of Elahere® 100 mg/20 mL injections?

Store the vials upright in a refrigerator at 2-8°C (36°F to 46°F) until the time of preparation in the original carton to protect them from light. Avoid freezing or shaking the vials.